

# Rare Cancers and Clinical Trials Progress in the Face of Rarity

Senapati Dulal\*

Department of Medicine & Advanced Technology, Monash University, Clayton, Victoria, Australia

## Abstract

Cancer is a formidable adversary, affecting millions of lives worldwide. While common cancers like breast, lung and prostate cancers dominate the public health landscape, there exists a group of malignancies that are far less prevalent but equally devastating - rare cancers. These rare cancers pose unique challenges for both patients and healthcare providers. However, there is hope on the horizon, as clinical trials are making significant progress in the face of rarity, offering new possibilities for those affected by these less common but often aggressive diseases. Rare cancers, also known as orphan cancers, are those with a lower incidence compared to more prevalent malignancies. Although no universal consensus defines the threshold for rarity, the American Cancer Society suggests that cancers with an incidence of fewer than six cases per 100,000 people per year fall into this category. Some examples of rare cancers include cholangiocarcinoma (bile duct cancer), mesothelioma and sarcomas.

**Keywords:** Cancer • Clinical trials • Rare cancers

## Introduction

Rare cancers, although individually infrequent, collectively impact a significant number of people. These lesser-known malignancies present unique challenges for both patients and the medical community, but clinical trials are playing a pivotal role in advancing our understanding and treatment of rare cancers. In this article, we will explore the importance of clinical trials for rare cancers, their benefits and how patients and researchers are working together to improve outcomes. The rarity of these cancers introduces unique challenges for patients and healthcare professionals. Due to their scarcity, rare cancers are often misdiagnosed or diagnosed at an advanced stage, leading to poorer prognoses [1]. Rare cancers often lack targeted therapies, leaving patients with fewer treatment options and they may have to rely on standard treatments that may not be as effective. Clinical knowledge and data for rare cancers are limited, making it challenging to develop evidence-based treatment guidelines.

Patients with rare cancers may feel isolated, as there are fewer support groups and resources available for them. Rare cancers receive less funding and research attention compared to common cancers, hindering progress in understanding and treating them. Clinical trials are research studies that involve human participants to evaluate the safety and effectiveness of medical interventions, such as new treatments, drugs, or therapies. Rare cancers often have unique genetic or molecular characteristics. Clinical trials help develop and test targeted therapies designed specifically to combat these distinct features, potentially resulting in more effective and less toxic treatments. Participation in clinical trials can provide access to cutting-edge treatments that might not be available through standard care. This expands the treatment arsenal for patients with rare cancers.

## Description

Clinical trials generate valuable data that contribute to a better

**\*Address for Correspondence:** Senapati Dulal, Department of Medicine & Advanced Technology, Monash University, Clayton, Victoria, Australia, E-mail: dulalsenapati@gmail.com

**Copyright:** © 2023 Dulal S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received:** 01 June, 2023, Manuscript No. jcc-23-118155; **Editor Assigned:** 03 June, 2023, Pre QC No. P-118155; **Reviewed:** 17 June, 2023, QC No. Q-118155; **Revised:** 22 June, 2023, Manuscript No. R-118155; **Published:** 29 June, 2023, DOI: 10.37421/2577-0535.2023.8.225

understanding of rare cancers. This knowledge can lead to the development of new diagnostic tools and treatment strategies, benefitting not only current patients but those in the future as well. Clinical trials often offer a multidisciplinary approach to care, connecting patients with medical experts who specialize in their specific condition. Additionally, participants in clinical trials become part of a community of individuals facing similar challenges, providing emotional and psychological support. In recognition of the limited treatment options for rare cancers, regulatory agencies often fast-track the review and approval of drugs for these conditions. This expedites the availability of new treatments to the patients who need them most. Patient participation in clinical trials is crucial for advancing the field of rare cancer research [2,3]. Patients who choose to enroll in trials not only have access to potentially groundbreaking treatments but also contribute significantly to the collective knowledge needed to develop better diagnostic and treatment strategies. In addition to participation, patient advocacy and support groups play a vital role in driving progress in rare cancer research. Here's how patients can get involved:

Patients and their families should actively seek information about available clinical trials. This can be done through their healthcare provider, rare cancer organizations, or online resources. Many rare cancer advocacy groups and non-profit organizations are dedicated to raising awareness, driving research and providing resources for patients. These groups can connect patients with clinical trial opportunities. Patients can advocate for their needs and those of the rare cancer community. This includes raising awareness about the importance of rare cancer research and the significance of clinical trials. For those who meet the criteria, participating in clinical trials can be a valuable way to contribute to the advancement of rare cancer treatment and help improve the lives of others facing similar diagnoses.

Raising awareness about the existence and significance of rare cancers is a critical first step. Many patients and healthcare providers may not be familiar with these conditions or available clinical trials. Clinical trials for rare cancers often struggle to recruit a sufficient number of participants due to the limited patient population. This can hinder the progress of research. Rare cancer research often receives less funding than more common cancers. Increased funding is essential to support more trials and accelerate the development of new treatments. Collaborative efforts to share data across institutions and borders are crucial for advancing research on rare cancers. Ensuring that the knowledge gained from one trial can benefit future studies is essential. While rare cancers may present unique challenges, the landscape is evolving. Advances in genomics, targeted therapies and the increasing recognition of the importance of rare cancer research are providing hope for patients and their families.

Clinical trials are at the forefront of this progress, offering an avenue to improved treatments, better outcomes and the possibility of turning rare cancers into more manageable conditions. Clinical trials are the cornerstone of

medical research and they play a crucial role in advancing the field of oncology. Clinical trials can lead to the discovery of targeted therapies, which have the potential to be more effective and less toxic than traditional treatments [4,5]. By participating in clinical trials, patients with rare cancers can access cutting-edge treatments that may not be available through standard care. Clinical trials generate valuable data that contribute to a better understanding of rare cancers, aiding in the development of new diagnostic tools and treatment strategies. Clinical trials often provide a support system for patients, connecting them with medical experts and a community of individuals facing similar challenges. Even if a clinical trial does not lead to a new treatment, it can provide valuable insights that pave the way for future research.

In recent years, there has been a growing awareness of the need to address rare cancers and progress in clinical trials is evident. Advances in genetic profiling and molecular biology have paved the way for precision medicine, allowing for the development of targeted therapies tailored to the specific genetic characteristics of a rare cancer. Patient advocacy groups and rare cancer organizations have been instrumental in raising awareness and driving research and clinical trial participation. Government agencies and regulatory bodies are increasingly recognizing the importance of rare cancer research, leading to increased funding and incentives for drug development in this space. Collaboration between researchers, institutions and countries is fostering a more comprehensive approach to studying and treating rare cancers. Regulatory agencies are expediting the review and approval of drugs for rare cancers, accelerating the availability of new treatments. Patients play a vital role in advancing the field of rare cancer research. By participating in clinical trials, patients not only gain access to cutting-edge treatments but also contribute to the collective knowledge needed to develop better diagnostic and treatment strategies. Patient engagement, advocacy and support networks are pivotal in driving progress in this underrepresented field of oncology.

## Conclusion

In conclusion, rare cancers present a unique set of challenges due to their limited incidence, but progress in clinical trials is gradually changing the landscape of care for these malignancies. With continued investment in research, increased awareness and patient participation, the outlook for individuals affected by rare cancers is becoming increasingly optimistic.

While there is much work to be done, the momentum is in the right direction, offering hope to those who face the daunting journey of battling rare cancers. Clinical trials for rare cancers are invaluable in advancing our understanding and treatment of these less common malignancies. By fostering patient participation, advocacy and research collaboration, we can overcome the challenges posed by rarity and provide new hope for those affected by these conditions. Rare cancers may be less common, but they are not forgotten and through clinical trials, they continue to receive the attention and care they deserve.

## References

1. Kokhan, Viktor S., Sofia Mariasina, Vladimir A. Pikalov and Denis A. Abaimov, et al. "Neurokinin-1 receptor antagonist reverses functional cns alteration caused by combined  $\gamma$ -rays and carbon nuclei irradiation." *CNS Neurol Disord Drug Targets* 21 (2022): 278-289.
2. McCorvy, John D. and Bryan L. Roth. "Structure and function of serotonin G protein-coupled receptors." *Pharmacol Ther* 150 (2015): 129-142.
3. Borman, R. A. and D. E. Burleigh. "5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine." *Ann N Y Acad Sci* 812 (1997): 222-223.
4. Bekal, Mahesh, Lue Sun, Susumu Ueno and Takashi Moritake. "Neurobehavioral effects of acute low-dose whole-body irradiation." *J Radiat Res* 62 (2021): 804-811.
5. Reisz, Julie A., Nidhi Bansal, Jiang Qian and Weiling Zhao, et al. "Effects of ionizing radiation on biological molecules—mechanisms of damage and emerging methods of detection." *Antioxid Redox Signal* 21 (2014): 260-292.

**How to cite this article:** Dulal, Senapati. "Rare Cancers and Clinical Trials Progress in the Face of Rarity." *J Cancer Clin Trials* 8 (2023): 225.